AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 93 min read$JNJ

Johnson & Johnson Reports Positive Two-Year Data on ICOTYDE for

Johnson & Johnson (JNJ) reported positive two-year Phase 3 trial results for ICOTYDE, an oral peptide for plaque psoriasis, with 72% of patients achieving significant skin improvement. The company offers a 1.98% dividend yield, a 55% payout ratio, and a 4.9% 3-year dividend growth rate, but its stock is 32% overvalued relative to its GF Value. JNJ has a GF Score of 83/100, indicating strong financial health and profitability, though insider activity shows significant net selling.

Original reporting
gurufocus.com
Published Oct 9, 2026, 11:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 12:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$JNJ
Bullish
high confidence
Mentioned
$JNJ
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

The trial results could drive a multi‑billion revenue opportunity if approved, influencing JNJ's growth outlook and valuation metrics.

02

Market read

First‑time disclosure of pivotal Phase 3 data for a major pharma, likely to affect JNJ stock and peers in the dermatology space.

03

What to watch

Potential regulatory hurdles, reimbursement uncertainty, and competition from existing biologics could temper long‑term impact.

Relevance 7/10Novelty 8/10Timing: today

Background

Johnson & Johnson is a diversified healthcare conglomerate with a strong dividend and a large market cap; the ICOTYDE trial adds to its immunology pipeline.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson announced positive two‑year Phase 3 ICONIC‑LEAD trial results for ICOTYDE, with >70% of patients achieving PASI90 and 44% achieving PASI100.

Expected impact

upward pressure as market prices in the potential launch of ICOTYDE.

Evidence & confidence

Phase 3 success for a novel oral psoriasis therapy represents a material pipeline catalyst for a large pharma with limited near‑term growth drivers.

Market effects

Sector

Strengthens the broader immunology/dermatology segment and may boost peer stocks awaiting similar data.

Regional

Positive for US healthcare equities, modest spillover to global pharma indices.

Global

Adds to the narrative of innovative pipeline growth for large-cap pharma worldwide.

Counterpoint

What could challenge this read

If pricing expectations are already baked in, the data may be a short‑term catalyst with limited upside.

Key entities

  • company
    Johnson & Johnson

    US‑listed healthcare conglomerate (NYSE: JNJ).

  • drug
    ICOTYDE

    Oral peptide targeting IL‑23 receptor for moderate‑to‑severe plaque psoriasis.

Read at source← All news

StoryJohnson & Johnson reports two‑year Phase 3 results for ICOTYDE in plaque psoriasis

Also covered by

1 outlet

Related articles

OCT 9
$JNJMed

Johnson & Johnson Reports Sustained Two-Year ICOTYDE Results In Plaque Psoriasis

Johnson & Johnson (JNJ) reported two-year results from its Phase 3 ICONIC-LEAD study of ICOTYDE for plaque psoriasis, showing sustained skin clearance and symptom improvements. At Week 112, 72% of patients achieved PASI 90, 70% had clear/almost clear skin, and 44% had complete clearance. Safety findings were consistent with the drug's profile. JNJ is also studying ICOTYDE for other conditions. JNJ closed at $256.48, down 0.76%, and was down 0.15% in premarket trading.

rttnews.com2 min
OCT 9
$JNJMed

At two years, at least 70% of patients on Johnson & Johnson’s psoriasis pill had clear or almost clear skin.

Johnson & Johnson (JNJ) reported two-year Phase 3 data for ICOTYDE in treating plaque psoriasis, showing 72% of patients achieved 90% skin improvement and 70% had clear/almost clear skin. Retreatment data showed 85% response recovery. No new safety issues were found. ICOTYDE is approved in major markets. Additional studies are ongoing for psoriasis, psoriatic arthritis, and inflammatory bowel diseases.

stocktitan.net3 min
OCT 9
$JNJMed

New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

Johnson & Johnson (JNJ) presented two-year Phase 3 data for ICOTYDE® (icotrokinra) at Fall Clinical Dermatology 2026. The study showed high, sustained response rates in adults and adolescents with plaque psoriasis, with 72% achieving clear or almost clear skin and a favorable safety profile. ICOTYDE is the first targeted oral peptide blocking the IL-23 receptor. The company highlights its potential as a first-line systemic therapy.

prnewswire.com2 min